Back

COVID-19 vaccine acceptability and inequity in the United States: Results from a nationally representative survey

Gibson, D. G.; Agarwal, S.; Meghani, A.; Limaye, R.; Labrique, A. B.

2021-02-02 epidemiology
10.1101/2021.01.29.21250784 medRxiv
Show abstract

BackgroundAt the time of this survey, September 1st, there were roughly 6 million COVID-19 cases and 176,771 deaths in the United States and no federally approved vaccine. The objective of this study was to explore the willingness to accept a COVID-19 vaccine in the United States and describe variability in this acceptability by key racial, ethnic and socio-demographic characteristics. MethodsThis was a cross-sectional digital survey that sampled participants from a nationally-representative panel maintained by a third party, Dynata. Dynata randomly sampled their database and emailed web-based surveys to United States residents ensuring the sample was matched to US Census estimates for age, race, gender, income, and Census region. Participants were asked how willing or unwilling they would be to: 1) receive a COVID-19 vaccine as soon as it was made publicly available, and 2) receive the influenza vaccine for the upcoming influenza season. Participants could respond with extremely willing, willing, unwilling, or extremely unwilling. For those who reported being unwilling to receive a COVID-19 vaccine, reasons for this hesitancy were captured. All participants were asked about where they obtain vaccine-related information, and which sources they trust most. Univariable and multivariable logistic regressions were conducted to examine the association of all demographic characteristics with willingness to receive COVID-19 vaccine. FindingsFrom September 1st to September 7, 2020, 1592 respondents completed the online survey. Overall, weighted analyses found that only 58.9% of the sample population were either willing or extremely willing to receive a COVID-19 vaccine as soon as it was made publicly available. In comparison, 67.7% of the respondents were willing or extremely willing to take the influenza vaccine. By gender, 66.1% of males and 51.5% of females were willing to receive a COVID-19 vaccine. Males were significantly more willing to receive a COVID-19 vaccine (adjusted odds ratio (OR)=1.98, 95% CI: 1.56, 2.53; p<0.001) than females. Blacks were the least willing racial/ethnic group (48.8%) Blacks, (aOR=0.59, 95%CI: 0.43, 0.80; p<0.001) were significantly less willing, than whites, to receive a COVID-19 vaccine. There were numerous reasons provided for being unwilling to receive a COVID-19 vaccine. The most common reason was concern about the vaccines safety (36.9%), followed by concerns over its efficacy (19.1%). InterpretationIn conclusion, we found that a substantial proportion (41%) of United States residents are unwilling to receive a COVID-19 vaccine as soon as one is made publicly available. We found that vaccine acceptance differs by sub-populations. In addition to sub-group differences in willingness to receive the vaccine, respondents provided a variety of reasons for being unwilling to receive the vaccine, driven by various sources of vaccine information (and misinformation). This compounds the challenge of delivering a safe and efficacious COVID-19 vaccine at a population level to achieve herd immunity. A multi-pronged and targeted communications and outreach effort is likely needed to achieve a high level of immunization coverage.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Vaccine
189 papers in training set
Top 0.1%
28.0%
2
Vaccines
196 papers in training set
Top 0.2%
10.2%
3
Vaccine: X
19 papers in training set
Top 0.1%
6.4%
4
PLOS ONE
4510 papers in training set
Top 31%
4.9%
5
BMC Public Health
147 papers in training set
Top 1%
4.0%
50% of probability mass above
6
Human Vaccines & Immunotherapeutics
25 papers in training set
Top 0.1%
4.0%
7
Preventive Medicine Reports
14 papers in training set
Top 0.1%
3.6%
8
JAMA Network Open
127 papers in training set
Top 0.9%
3.6%
9
American Journal of Preventive Medicine
11 papers in training set
Top 0.2%
1.7%
10
BMJ Open
554 papers in training set
Top 9%
1.7%
11
BMC Infectious Diseases
118 papers in training set
Top 3%
1.7%
12
JMIR Public Health and Surveillance
45 papers in training set
Top 2%
1.5%
13
Frontiers in Public Health
140 papers in training set
Top 6%
1.3%
14
Open Forum Infectious Diseases
134 papers in training set
Top 2%
1.3%
15
Clinical Infectious Diseases
231 papers in training set
Top 3%
1.3%
16
Influenza and Other Respiratory Viruses
44 papers in training set
Top 0.3%
1.2%
17
Healthcare
16 papers in training set
Top 1%
1.1%
18
Pharmacoepidemiology and Drug Safety
13 papers in training set
Top 0.3%
1.0%
19
PLOS Medicine
98 papers in training set
Top 4%
0.9%
20
JAMA
17 papers in training set
Top 0.2%
0.9%
21
American Journal of Epidemiology
57 papers in training set
Top 1%
0.9%
22
Preventive Medicine
11 papers in training set
Top 0.2%
0.9%
23
International Journal of Medical Informatics
25 papers in training set
Top 1%
0.8%
24
The Lancet Regional Health - Americas
22 papers in training set
Top 0.3%
0.8%
25
Journal of Racial and Ethnic Health Disparities
11 papers in training set
Top 0.6%
0.5%
26
Scientific Reports
3102 papers in training set
Top 80%
0.5%
27
International Journal of Epidemiology
74 papers in training set
Top 3%
0.5%
28
Epidemiology
26 papers in training set
Top 0.7%
0.5%
29
Journal of General Internal Medicine
20 papers in training set
Top 1%
0.5%